We are live on ! Find out more
CRBP icon

Corbus Pharmaceuticals
CRBP

64 hedge funds and large institutions have $3.86M invested in Corbus Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 14 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

110% more call options, than puts

Call options by funds: $65K | Put options by funds: $31K

0.22% less ownership

Funds ownership: 0.85% → 0.62% (-0.22%)

9% less funds holding

Funds holding: 70 → 64 (-6)

29% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 14

42% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 12

52% less capital invested

Capital invested by funds: $8.04M → $3.86M (-$4.18M)

Holders
64
Holders Change
-6
Holders Change %
-8.57%
% of All Funds
1.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
10
Reduced
14
Closed
12
Calls
$65K
Puts
$31K
Net Calls
+$34K
Net Calls Change
-$26K

Top Buyers

Rank Fund Capital Flow
1
ECM
ExodusPoint Capital Management
New York
+$85.2K
2
Two Sigma Investments
Two Sigma Investments
New York
+$10.7K
3
UBS Group
UBS Group
Switzerland
+$9.53K
4
KCIA
Kingsbury Capital Investment Advisors
Illinois
+$7.92K
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$7.29K

Top Sellers

Rank Fund Capital Flow
1
Mirae Asset Global Investments
Mirae Asset Global Investments
South Korea
-$853K
2
EMG
ETF Managers Group
New Jersey
-$553K
3
Renaissance Technologies
Renaissance Technologies
New York
-$197K
4
IEFM
IQ EQ Fund Management
Ireland
-$115K
5
IC
Ikarian Capital
Texas
-$109K
Name Holding Trade Value Shares
Change 		Change in
Stake
Cambridge Investment Research Advisors
26
Cambridge Investment Research Advisors
Iowa
$12K +$99 +14 +0.6%
Verition Fund Management
27
Verition Fund Management
Connecticut
$11K – – –
T. Rowe Price Associates
28
T. Rowe Price Associates
Maryland
$10K – – –
BFM
29
Boothbay Fund Management
New York
$7K -$12.9K -1,831 -58%
JP Morgan Chase
30
JP Morgan Chase
New York
$7K -$2.28K -323 -18%
UBS Group
31
UBS Group
Switzerland
$7K +$9.53K +1,352 +2,080%
JEST
32
JTC Employer Solutions Trustee
Jersey
$6K – – –
KCIA
33
Kingsbury Capital Investment Advisors
Illinois
$6K +$7.92K +1,123 New
CWA
34
CJM Wealth Advisers
Virginia
$5.03K – – –
Bank of New York Mellon
35
Bank of New York Mellon
New York
$5K – – –
Mercer Global Advisors
36
Mercer Global Advisors
Colorado
$5K – – –
SPC
37
Sigma Planning Corp
Michigan
$5K – – –
Royal Bank of Canada
38
Royal Bank of Canada
Ontario, Canada
$5K +$7.29K +1,034 +34,467%
KAS
39
Kestra Advisory Services
Texas
$3K – – –
Neuberger Berman Group
40
Neuberger Berman Group
New York
$3K – – –
SF
41
Synovus Financial
Georgia
$3K – – –
Two Sigma Advisers
42
Two Sigma Advisers
New York
$3K +$3.95K +560 New
Millennium Management
43
Millennium Management
New York
$2K -$79.3K -11,245 -97%
AWM
44
Aries Wealth Management
Maine
$2K – – –
GL
45
Graypoint LLC
New York
$2K – – –
HighTower Advisors
46
HighTower Advisors
Illinois
$2K – – –
IA
47
IFP Advisors
Florida
$2K – – –
ML
48
McAdam LLC
Pennsylvania
$2K – – –
AWAG
49
ARS Wealth Advisors Group
Florida
$2K +$2.35K +333 New
CG
50
Cutler Group
California
$1K – – –
1
2
3

CRBP Hedge Fund Activity: Q3 2022 in Review

64 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q3 2022, worth a combined $3.86M — down 52% from $8.04M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of CRBP and 7 opened new positions — a net loss of 5 holders — while 14 trimmed existing stakes and 10 added.

The largest buyer was ExodusPoint Capital Management, opening a new position worth an estimated $85.2K. The largest seller was Mirae Asset Global Investments, cutting an estimated $853K.

  • 64 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q3 2022, down from 70 in Q2 2022.
  • Funds reported $3.86M of Corbus Pharmaceuticals stock for Q3 2022, down 52% quarter-over-quarter.
  • 7 funds opened new Corbus Pharmaceuticals positions in Q3 2022 and 12 closed out, a net change of -5 holders.
  • The largest Corbus Pharmaceuticals buyer in Q3 2022 was ExodusPoint Capital Management, an estimated $85.2K added.
  • The largest Corbus Pharmaceuticals seller in Q3 2022 was Mirae Asset Global Investments, an estimated $853K sold.

Based on aggregated 13F filings for Q3 2022.